Alabama Academy of Family Physicians
MAY 15, 2025
What Happened: The Senate Committee on Finance and Taxation Education did not meet to discuss the bill. Pharmacy benefits managers would be further required to pass on 100 percent of rebates received from drug manufacturers to the health benefit plans for which they provide services.
Minnesota Academy of Family Physicians
MARCH 27, 2025
HOUSE COMMERCE FINANCE AND POLICY COMMITTEE H.F. 2403 ( Representative O’Driscoll ): On Wednesday, March 19, 2025, the House Commerce Finance and Policy Committee heard H.F. The Minnesota Hospital Association, as well as some individual hospitals, testified in support of the bill. Read a summary of S.F. Read a summary of H.F.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
FDA Law
DECEMBER 28, 2021
See section 129001 of the most recent Finance Committee text.) The bipartisan idea of international reference pricing generated considerable controversy during its short lifetime. The November 2020 rule was promptly challenged in four lawsuits, one of which resulted in a nationwide preliminary injunction against its implementation.
FDA Law
DECEMBER 28, 2021
See section 129001 of the most recent Finance Committee text.) The bipartisan idea of international reference pricing generated considerable controversy during its short lifetime. The November 2020 rule was promptly challenged in four lawsuits, one of which resulted in a nationwide preliminary injunction against its implementation.
FDA Law
JUNE 27, 2022
If and when implemented, the amendments will likely force Medicare Part D plans and their PBMs to pass drug manufacturer rebates through to pharmacies to reduce out-of-pocket expenses of Part D enrollees, which would be a dramatic change from current practice.
FDA Law
AUGUST 10, 2021
Use of international reference pricing as a target for Medicare to negotiate prices with drug manufacturers appears in H.R. According to the proposal, CMS will review the issues identified by commenters and continue to explore opportunities to address high drug costs based on stakeholder comments to the interim final rule.
FDA Law
SEPTEMBER 13, 2021
A final OIG rule to change the structure of manufacturer rebates to Medicare Part D and Medicaid Managed Care plans and their PBMs is enmeshed in litigation and is likely to be at least postponed until 2026 (see our post ), and perhaps prevented from implementation altogether, by Congressional mandate. Last Thursday, the U.S.
Expert insights. Personalized for you.
130 
Let's personalize your content